Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 100 participants.
Also called NCT06030544
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Spanish National Research Council
- Registry
-
NCT06030544
-
- Other papers using this trial's data
- Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06030544. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-25 (actual); primary completion 2025-03-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)
- Acronym
- OLTRAD
- Condition
- Diabetic Patients
- Condition
- Type II Diabetes Mellitus
- Intervention (Dietary supplement)
- OA-enriched functional olive oil
- Intervention (Dietary supplement)
- commercial olive oil
- Lead sponsor
- Spanish National Research Council
- Collaborator
- Andalusian Health Service
- Collaborator
- Universidad Pablo de Olavide
Record details
- Record id
cardio:ct-nct06030544- Content hash
01810661ce70da2ecff756b0a5043f20eed80b6e0fb3e1579b535a8fc1a87280